BRPI1007443B8 - método para diagnosticar nefropatia diabética em um indivíduo, método para avaliar a eficácia de um tratamento para nefropatia diabética em um indivíduo, método para determinação do estágio da nefropatia diabética em um indivíduo, método para monitoramento do progresso da nefropatia diabética em um indivíduo, e método para avaliar a eficácia de um tratamento para nefropatia diabética em um indivíduo - Google Patents

método para diagnosticar nefropatia diabética em um indivíduo, método para avaliar a eficácia de um tratamento para nefropatia diabética em um indivíduo, método para determinação do estágio da nefropatia diabética em um indivíduo, método para monitoramento do progresso da nefropatia diabética em um indivíduo, e método para avaliar a eficácia de um tratamento para nefropatia diabética em um indivíduo

Info

Publication number
BRPI1007443B8
BRPI1007443B8 BRPI1007443A BRPI1007443A BRPI1007443B8 BR PI1007443 B8 BRPI1007443 B8 BR PI1007443B8 BR PI1007443 A BRPI1007443 A BR PI1007443A BR PI1007443 A BRPI1007443 A BR PI1007443A BR PI1007443 B8 BRPI1007443 B8 BR PI1007443B8
Authority
BR
Brazil
Prior art keywords
diabetic nephropathy
individual
effectiveness
treatment
urine
Prior art date
Application number
BRPI1007443A
Other languages
English (en)
Inventor
Li Hung-Yi
Chen Jin-Shuen
Ya-Ping Yeh Mary
Cheng Ping-Fu
Hsu Tsai-Wei
Tseng Tzu-Ling
Lin Wei-Ya
Li Yen-Peng
Chen Yi-Ting
Lin Yuh-Feng
Original Assignee
Bio Preventive Medicine Corp
Ind Tech Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Preventive Medicine Corp, Ind Tech Res Inst filed Critical Bio Preventive Medicine Corp
Publication of BRPI1007443A2 publication Critical patent/BRPI1007443A2/pt
Publication of BRPI1007443B1 publication Critical patent/BRPI1007443B1/pt
Publication of BRPI1007443B8 publication Critical patent/BRPI1007443B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4728—Details alpha-Glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G01N2333/8125—Alpha-1-antitrypsin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

biomarcadores séricos e de urina associados á nefropatia diabética. uso de biomarcadores de urina e séricos no diagnostico de nefropatia diabética, estadiamento da nefropatia diabética, monitoramento do progreeso da nefropatia diabética e avaliação da eficácia dos tratamentos da nefropatia diabética. estes marcadores incluem alfa-2-hs-glicoproteína precussora da urina, alfa-1 antitripsina da urina, alfa-1 glicoproteína ácida da urina, osteopontina da urina, osteopontina do soro e seus fragmentos e combinações das mesmas.
BRPI1007443A 2009-01-28 2010-01-27 método para diagnosticar nefropatia diabética em um indivíduo, método para avaliar a eficácia de um tratamento para nefropatia diabética em um indivíduo, método para determinação do estágio da nefropatia diabética em um indivíduo, método para monitoramento do progresso da nefropatia diabética em um indivíduo, e método para avaliar a eficácia de um tratamento para nefropatia diabética em um indivíduo BRPI1007443B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14777809P 2009-01-28 2009-01-28
US61/147,778 2009-01-28
PCT/CA2010/000097 WO2010085879A1 (en) 2009-01-28 2010-01-27 Urine and serum biomarkers associated with diabetic nephropathy

Publications (3)

Publication Number Publication Date
BRPI1007443A2 BRPI1007443A2 (pt) 2017-09-12
BRPI1007443B1 BRPI1007443B1 (pt) 2020-10-13
BRPI1007443B8 true BRPI1007443B8 (pt) 2021-07-27

Family

ID=42395076

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1007443A BRPI1007443B8 (pt) 2009-01-28 2010-01-27 método para diagnosticar nefropatia diabética em um indivíduo, método para avaliar a eficácia de um tratamento para nefropatia diabética em um indivíduo, método para determinação do estágio da nefropatia diabética em um indivíduo, método para monitoramento do progresso da nefropatia diabética em um indivíduo, e método para avaliar a eficácia de um tratamento para nefropatia diabética em um indivíduo

Country Status (14)

Country Link
US (4) US8465980B2 (pt)
EP (2) EP2623517B8 (pt)
JP (1) JP5689426B2 (pt)
CN (1) CN102300877B (pt)
BR (1) BRPI1007443B8 (pt)
CA (1) CA2748937C (pt)
DK (2) DK2391654T3 (pt)
ES (2) ES2552557T3 (pt)
HU (2) HUE025795T2 (pt)
MX (1) MX2011007811A (pt)
PL (2) PL2391654T3 (pt)
PT (2) PT2391654E (pt)
TW (1) TWI449910B (pt)
WO (1) WO2010085879A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2391653E (pt) * 2009-01-28 2015-02-13 Ind Tech Res Inst Biomarcadores associados a nefropatia
CN103299192B (zh) * 2010-09-21 2016-05-11 普罗蒂阿米克斯国际有限公司 与糖尿病前期、糖尿病以及糖尿病相关病症相关的生物标记
JP5714285B2 (ja) * 2010-09-29 2015-05-07 株式会社プロトセラ 妊娠高血圧症候群マーカーおよびそれを用いた診断
EP2592421B1 (en) * 2011-11-14 2017-08-30 Universitätsklinikum Jena Diagnosis of sepsis and systemic inflammatory response syndrome
JP2013178239A (ja) * 2012-01-31 2013-09-09 Ajinomoto Co Inc 早期腎症の評価方法、早期腎症評価装置、早期腎症評価方法、早期腎症評価プログラム、早期腎症評価システムおよび情報通信端末装置
WO2013122976A1 (en) * 2012-02-13 2013-08-22 New York University Osteopontin isoform a inhibitors and methods of use
GB201203938D0 (en) * 2012-03-06 2012-04-18 Binding Site Group The Ltd Assay system
CA2818328C (en) 2012-06-11 2017-09-05 Preventage Healthcare Llc Methods for improving diabetes management
EP3066476A2 (en) * 2013-11-04 2016-09-14 The Regents of the University of Michigan Biomarkers and methods for progression prediction for chronic kidney disease
CN103804484B (zh) * 2014-01-24 2016-03-16 南京必优康生物技术有限公司 一种网红细胞生长因子及其制备方法和应用
CN105572355B (zh) * 2015-03-13 2018-04-13 中国医学科学院肿瘤医院 检测食管癌的生物标志物
US11216742B2 (en) 2019-03-04 2022-01-04 Iocurrents, Inc. Data compression and communication using machine learning
CN114487431A (zh) * 2020-11-12 2022-05-13 首都医科大学附属北京世纪坛医院 尿液α-2-HS-糖蛋白及其多肽片段在妊娠糖尿病中的应用
CN113687083B (zh) * 2021-08-20 2023-11-28 天津中医药大学 一种基于深度学习的糖尿病肾病早期预测方法及系统

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015904A1 (en) 1997-09-26 1999-04-01 University Of Washington Methods and compositions for diagnosing renal pathologies
JP2002090365A (ja) * 2000-02-08 2002-03-27 Internatl Reagents Corp 腎障害の検査手段
DE60029302T2 (de) * 2000-04-28 2007-08-09 Bayer Ag Diagnose von Leberfibrose mit Hilfe von Serummarkeralgorithmen
IL153206A0 (en) * 2000-06-13 2003-07-06 Childrens Medical Center Biosynthetic oncolytic molecules and uses therefor
DK1345969T3 (da) * 2000-12-26 2010-11-29 Inst Nat Sante Rech Med Anti-CD28-antistof
WO2003019193A1 (en) * 2001-08-30 2003-03-06 Ciphergen Biosystems, Inc. Method of diagnosing nephrotic syndrome
US20040171081A1 (en) * 2001-11-23 2004-09-02 Abraham Mittelman Antigens
WO2004082617A2 (en) * 2003-03-14 2004-09-30 Ppd Biomarker Discovery Sciences, Llc Biological markers for diagnosing rheumatoid arthritis
US20060286602A1 (en) * 2004-05-10 2006-12-21 Harald Mischak Method and markers for the diagnosis of renal diseases
US20050266467A1 (en) * 2004-05-19 2005-12-01 Ppd Biomarker Discovery Sciences, Llc Biomarkers for multiple sclerosis and methods of use thereof
WO2006044666A2 (en) * 2004-10-15 2006-04-27 Northeastern University Detection of disease associated proteolysis by direct mass spectrometry analysis of low molecular weight peptides
DK1806359T3 (da) * 2005-09-05 2010-06-14 Immatics Biotechnologies Gmbh Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler
EP1946121A2 (en) * 2005-10-27 2008-07-23 Yale University, Inc. Urinary proteomic biomarker patterns in preeclampsia
US20070111245A1 (en) * 2005-11-09 2007-05-17 Ravi Thadhani Predicting diabetic nephropathy
WO2007110230A2 (en) * 2006-03-27 2007-10-04 Institut Pasteur Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections
JP5244103B2 (ja) * 2006-08-09 2013-07-24 ホームステッド クリニカル コーポレイション 器官特異的蛋白質およびその使用方法
WO2008092214A1 (en) 2007-02-02 2008-08-07 Minomic International Limited Biomarkers for diabetes
EP2479565A3 (en) 2007-03-26 2012-09-26 Novartis AG Predictive renal safety biomarkers and biomarker signatures to monitor kidney function
US20110214990A1 (en) * 2008-09-17 2011-09-08 Mosaiques Diagnostics And Therapeutics Ag Kidney cell carcinoma
PT2391653E (pt) * 2009-01-28 2015-02-13 Ind Tech Res Inst Biomarcadores associados a nefropatia

Also Published As

Publication number Publication date
HUE025795T2 (en) 2016-05-30
EP2623517B8 (en) 2015-12-30
US20130252267A1 (en) 2013-09-26
JP2012516431A (ja) 2012-07-19
EP2391654B1 (en) 2015-09-09
DK2623517T3 (en) 2015-11-23
JP5689426B2 (ja) 2015-03-25
EP2623517A1 (en) 2013-08-07
CA2748937C (en) 2016-07-19
CN102300877B (zh) 2014-12-10
BRPI1007443A2 (pt) 2017-09-12
MX2011007811A (es) 2012-03-14
ES2552467T3 (es) 2015-11-30
US10101340B2 (en) 2018-10-16
ES2552557T3 (es) 2015-11-30
DK2391654T3 (en) 2015-11-16
EP2391654A4 (en) 2012-08-01
PT2623517E (pt) 2015-11-19
TWI449910B (zh) 2014-08-21
CN102300877A (zh) 2011-12-28
PT2391654E (pt) 2015-11-19
WO2010085879A1 (en) 2010-08-05
US20110086371A1 (en) 2011-04-14
BRPI1007443B1 (pt) 2020-10-13
EP2623517B1 (en) 2015-09-16
CA2748937A1 (en) 2010-08-05
TW201033616A (en) 2010-09-16
US8476077B2 (en) 2013-07-02
HUE025796T2 (hu) 2016-05-30
US8465980B2 (en) 2013-06-18
PL2623517T3 (pl) 2016-04-29
US20110079077A1 (en) 2011-04-07
PL2391654T3 (pl) 2016-04-29
EP2391654A1 (en) 2011-12-07
US20100197033A1 (en) 2010-08-05

Similar Documents

Publication Publication Date Title
BRPI1007443B8 (pt) método para diagnosticar nefropatia diabética em um indivíduo, método para avaliar a eficácia de um tratamento para nefropatia diabética em um indivíduo, método para determinação do estágio da nefropatia diabética em um indivíduo, método para monitoramento do progresso da nefropatia diabética em um indivíduo, e método para avaliar a eficácia de um tratamento para nefropatia diabética em um indivíduo
EP4303584A3 (en) Methods for detecting signatures of disease or conditions in bodily fluids
WO2010135692A3 (en) Mirna biomarkers of prostate disease
MX2011003174A (es) Biomarcadores urinarios para predecir dialisis a largo plazo.
BRPI0906549A2 (pt) Bandagens médicas com válvulas e kits contendo as mesmas.
WO2011054893A3 (en) Biomarkers predictive of progression of fibrosis
WO2009117468A3 (en) Property rental transactions, property management, and assessing performance of landlords and tenants
WO2011022369A3 (en) Method for processing tissues
BRPI0906093A2 (pt) sistema de tratamento com pressão reduzida, curativo com pressão reduzida adaptado pra distribuir uma pressão reduzida a um sítio tecidual, método para coletar fluido em um curativo posicionado em um sítio tecidual e kit de curativo com pressão reduzida.
MX356986B (es) Metodo para detectar aductos de nucleosomas.
WO2012031008A3 (en) Cancer-related biological materials in microvesicles
CL2012001103A1 (es) Método para reducir el nivel del polipéptido tau desacetilado en una célula, que comprende poner en contacto la célula con un agente que incrementa la actividad de un polipéptido que desacetila tau y/o un agente que disminuye la actividad de un polipéptido que acetila tau; y usos terapéuticos para tratar una tauopatía.
WO2009132273A3 (en) Microrna biomarkers of tissue injury
BR112012030587A2 (pt) métodos para diagnóstico de câncer pancreático, para identificar se um indivíduo precisa ou não de uma terapia contra câncer pancreático e para determinar se uma terapia contra câncer pancreático obtém sucesso, dispositivo para diagnóstico de câncer pancreático e uso de pelo menos um biomarcador
WO2012104620A3 (en) Wound prognosis
WO2013159872A8 (en) Biomarkers for the diagnosis, prognosis, assessment and therapy stratification of syncope
BR112012014678A2 (pt) "uso do dna mrna, método para o diagnóstico da rosácea e método de monitoramento"
BRPI1015927A2 (pt) Kit e método para diagnosticar uma doença de tireoide e método para diagnosticar o hipotireoidismo, bem como célula e seu uso
EP2666019A1 (en) Methods and kits for predicting the risk of respiratory failure, renal failure or thrombopenia in a septic patient by measuring endocan levels in blood
WO2014187884A3 (en) Mirnas as non-invasive biomarkers for heart failure
BRPI0921454A2 (pt) métodos para tratar um paciente com câncer, e para identificar células tronco cancerosas
BRPI0914921A2 (pt) métodos para diagnosticar doença pulmonar obstrutiva crônica em um paciente humano ou o risco de um paciente humano desenvolver doença pulmonar obstrutiva crônica, para a discriminação entre doença pulmonar obstrutiva crônica estágio i/ii e doença pulmonar obstrutiva crônica estágio iii/iv e para monitorar o progresso de doença pulmonar obstrutiva crônica em um paciente humano
WO2012078618A3 (en) Predicting and treating diabetic complications
WO2012145399A3 (en) Methods of diagnosing cancer in a patient
WO2008012692A3 (en) Assay for efficacy of histone deacetylase inhibitors

Legal Events

Date Code Title Description
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25A Requested transfer of rights approved

Owner name: BIO PREVENTIVE MEDICINE CORPORATION (TW)

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/01/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO